May 10, 2022 / 06:20PM GMT
Craig William Bijou - BofA Securities, Research Division - Research Analyst
Good afternoon. My name is Craig Bijou. I'm one of the analysts here at BofA. It's a pleasure to welcome Teleflex. And from the company, we have Liam Kelly, CEO; Larry Keusch, VP of IR and Strategy Development; and John Hsu, VP of IR. So welcome. Thank you, guys, for coming.
Liam J. Kelly - Teleflex Incorporated - Chairman, President & CEO
Thanks for having us.
Questions and Answers:
Craig William Bijou - BofA Securities, Research Division - Research AnalystI want to start with UroLift. No big surprise there. But maybe if you can just kind of go back a couple of weeks, you reported, just give us a sense of from the COVID perspective, the procedure trends and just what you saw throughout Q1 and then that's kind of -- what you've seen thus far in April?
Liam J. Kelly - Teleflex Incorporated - Chairman, President & CEO
Yes. So what we saw in Q1, obviously, Omicron was with us in January
Trustpilot
